Cinda Biologics ( 01801.HK ) 2025 Annual Performance: Revenue successfully surpasses 10 billion, achieving its first full-year profit

NightAirdropper · 2026-03-27T14:39:56+00:00

In 2025, the company's total revenue reached 13.042 billion yuan, a year-on-year increase of 38.4%, marking its first full-year profit with a net profit of 81.36 billion yuan, corresponding to a Non-IFRS net profit of 17.231 billion yuan, primarily driven by strong revenue growth and improved operational efficiency. Product revenue and licensing fee income saw significant growth, while R&D expenses remained stable, demonstrating the company's ongoing investment in innovation and strategic initiatives.

NightAirdropper

2026-03-27 14:39:56

Abstract generation in progress

Gelonghui March 26丨Announced annual performance, for the year ending December 31, 2025, the company achieved total revenue of RMB 13,041.5 million, a year-on-year increase of 38.4%. For the first time in seven years since the launch of the first product, the company’s revenue has exceeded RMB 10 billion, and it continues to maintain rapid growth, setting a record in the domestic pharmaceutical industry.

The company achieved its first annual profit, marking the official entry of the group into a new era of sustainable profitability. The net profit according to International Financial Reporting Standards (“IFRS”) reached RMB 813.6 million. Non-IFRS net profit grew to RMB 1,723.1 million (compared to RMB 331.6 million in 2024), and Non-IFRS earnings before interest, taxes, depreciation, and amortization (“EBITDA”) increased to RMB 1,990.7 million (compared to RMB 411.6 million in 2024). The leap in profitability is mainly attributed to the significant scale effects from strong revenue growth and the continuous improvement in operational efficiency.

During the period, total revenue mainly consisted of product revenue and licensing fee revenue. Product revenue was RMB 11,895.9 million, a year-on-year increase of 44.6%. This growth was primarily due to the sustained leading advantage in the oncology field and the rapid expansion of the comprehensive product line. Licensing fee revenue was RMB 957.3 million, and with the increase in cooperative pipelines and the deepening of strategic cooperation, licensing fee revenue has become an important source of income for the company.

Research and development expenses were RMB 2,624.2 million, compared to RMB 2,681.1 million in 2024. During the reporting period, the company continued to make strategic investments in late-stage assets and early pipelines, demonstrating excellence in execution in the R&D field. Meanwhile, we continue to advance the next generation of innovative pipelines into global development.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes